Summary:
- The article discusses the scientific and public health challenges surrounding the rollout of Lenacapavir, a novel, long-acting injectable antiretroviral drug for HIV prevention (PrEP).
- It analyzes the logistical, economic, and manufacturing complexities involved in scaling up access to this pharmaceutical innovation in South Africa and Zambia, focusing on the tension between patent-protected supply chains and the urgent clinical need for high-efficacy prevention tools.